Loading clinical trials...
Loading clinical trials...
A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2 Infusion) in Chemonaive, Elderly Patients With Locally Advanced (Stage IIIB) or Metastatic (Stage IV) NSCLC
Conditions
Interventions
Gefitinib
Vinorelbine
Locations
55
Australia
Research Site
St Leonards, New South Wales, Australia
Research Site
Westmead, New South Wales, Australia
Research Site
South Brisbane, Queensland, Australia
Research Site
Nedlands, Western Australia, Australia
Research Site
Victoria, Australia
Research Site
Fortaleza, Ceará, Brazil
Start Date
July 1, 2004
Completion Date
February 1, 2006
Last Updated
April 23, 2009
NCT06487078
NCT06461338
NCT04738487
NCT04990479
NCT03950674
NCT03770299
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions